

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)


TRANSMITTAL FORM <i>(To be used for all correspondence after initial filing)</i>	Application Number	10/729,822
	Filing Date	December 5, 2003
	First Named Inventor	Ronald Berenson
	Art Unit	1632
	Examiner Name	
	Attorney Docket No.	980034.422C1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Forms PTO-1449 (3 Sheets) <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): <hr/> <hr/> <hr/> <hr/>
--	---	--


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D., Patent Agent	Customer Number
		00500
Signature		
Date	May 7, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Lawrence Teague	
Signature		Date: May 7, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


1489509



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 7, 2004
Date


Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald Berenson et al.
Application No. : 10/729,822
Filed : December 5, 2003
For : COMPOSITIONS AND METHODS FOR ELIMINATING
UNDESIRED SUBPOPULATIONS OF T CELLS IN PATIENTS
WITH IMMUNOLOGICAL DEFECTS RELATED TO
AUTOIMMUNITY AND ORGAN OR HEMATOPOIETIC STEM
CELL TRANSPLANTATION

Art Unit : 1632
Docket No. : 980034.422C1
Date : May 7, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 10/603,577, filed June 24, 2003. The references

cited of the attached forms PTO-1449 were submitted to and/or cited by the Office in this prior application and, therefore, are not required to be provided in the present application.

As to any reference previously supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461


JAU:ljt

Enclosures:

Postcard
Transmittal Form
Forms PTO-1449 (3 Sheets)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

1479459



FORM PTO-1449 (REV.7.80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE December 5, 2003	GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,837,447	11/17/98	Gorski	435	6	
	AB	5,858,358	01/12/99	June et al.	424	130.1	
	AC	5,883,223	03/16/99	Gray	530	328	
	AD	6,352,694	03/05/02	June et al.	424	93.71	
	AE	2003/0119185	06/26/03	Berenson et al.	435	372	
	AF	2003/0124122	07/03/03	Berenson et al.	424	144.1	
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	WO 94/28926	12/22/94	WIPO		
	AL	WO 95/33823	12/14/95	WIPO		
	AM					
	AN					
	AO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		U.S. Serial No. 10/350,305 entitled "Activation and Expansion of Cells," filed January 22, 2003.
AQ		U.S. Serial No. 60/375,733 entitled "Compositions and Method for Restoring Immune Responsiveness in Patients with Immunological Defects," filed April 26, 2002.
AR		Berge et al., "Selective Expansion of a Peripheral Blood CD8 ⁺ Memory T Cell Subset Expressing Both Granzyme B and L-Selectin During Primary Viral Infection in Renal Allograft Recipients," <i>Transplantation Proceedings</i> 30:3975-3977, 1988.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>		APPLICANTS		Ronald Berenson et al.	
		FILING DATE December 5, 2003		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	BB				

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

BC		Bretscher, P., "The Two-Signal Model of Lymphocyte Activation Twenty-One Years Later," <i>Immunology Today</i> 13(2):74-76, 1992.
BD		Bierer, B. et al., "Cyclosporin A And FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology," <i>Curr. Opin. Immun.</i> 5(5):763-773, 1993.
BE		Cohen, P. et al., "Propagation of Mouse and Human T Cells with Defined Antigen Specificity and Function," <i>CIBA Foundation Symp.</i> 187:179-197, 1994.
BF		Fowler, D. et al., "Donor CD4-Enriched Cell of Th2 Cytokine Phenotype Regulate Graft Versus-Host Disease without Impairing Allogeneic Engraftment in Sublethally Irradiated Mice," <i>Blood</i> 87(10):3540-3549, 1994.
BG		Garland, R. et al., "The Use of Teflon Cell Culture Bags to Expand Functionally Active CD8 ⁺ Cytotoxic T Lymphocytes," <i>J. Immunol. Meth.</i> 227(1-2):53-63, 1999.
BH		Haanen, J. et al., "Selective Expansion of Cross-Reactive CD8+ Memory T Cells by Viral Variants," <i>J. Exp. Med.</i> 190(9):1319-1328, November 1999.
BI		Henderson, D. et al., "Comparison of the Effects of FK-506, Cyclosporin A and Rapamycin on IL-2 Production," <i>Immunology</i> 73(3):316-321, July 1991.
BJ		June, C. et al., "The B7 and CD28 Receptor Families," <i>Immunology Today</i> 15(7):321-331, 1994.
BK		Liu, J. et al., "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes," <i>Cell</i> 66:807-815, 1991.
BL		Liuzzo, G. et al., "Perturbation of the T-Cell Repertoire in Patients with Unstable Angina," <i>Circulation</i> 100:2135-2139, November 1999.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>				ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822			
				APPLICANTS Ronald Berenson et al.				
				FILING DATE December 5, 2003	GROUP ART UNIT 1632			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	CA							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
	CB							
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
CC		Sakaguchi, S. et al., "Immunologic Tolerance Maintained by CD25 ⁺ CD4 ⁺ Regulatory T Cells: Their Common Role in Controlling Autoimmunity, Tumor Immunity, and Transplantation Tolerance," <i>Immunological Reviews</i> 182:18-32, August 2001.						
CD		Salomon, B. et al., "B7/CD28 Costimulation is Essential for the Homeostasis of the CD4 ⁺ CD25 ⁺ Immunoregulatory T Cells that Control Autoimmune Diabetes," <i>Immunity</i> 12:431-440, April 2000.						
CE		Schmidt, D. et al., "The Repertoire of CD4 ⁺ CD28 ⁻ T Cells in Rheumatoid Arthritis," <i>Molecular Medicine</i> 2(5):11076-1551, September 1996.						
CF		Shevach, E. et al., "Regulatory T Cells in Autoimmunity," <i>Annu. Rev. Immunol.</i> 18:423-449, 2000.						
CG		Stephens, L. et al., "Human CD4 ⁺ CD25 ⁺ Thymocytes and Peripheral T Cells have Immune Suppressive Activity in Vitro," <i>Eur. J. Immunol.</i> 31:1247-1254, 2001.						
CH		Weyand, C. et al., "Functional Properties of CD4+ CD28- T Cells in the Aging Immune System," <i>Mech. of Ageing and Development</i> 102(2&3):131-147, May 1998.						
CI		Woo, E. et al., "Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation," <i>J. Immunol.</i> 168(9):4272-4276, May 2002.						
CJ								
CK								
CL								
EXAMINER				DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).								